Loading…
Pathological findings of progressive renal involvement in a patient with TAFRO syndrome
TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old w...
Saved in:
Published in: | CEN case reports 2019-11, Vol.8 (4), p.239-245 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053 |
---|---|
cites | cdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053 |
container_end_page | 245 |
container_issue | 4 |
container_start_page | 239 |
container_title | CEN case reports |
container_volume | 8 |
creator | Saito, Hirotaka Tanaka, Kenichi Fujiwara, Momoko Iwasaki, Tsuyoshi Numata, Tokutaro Oda, Akira Kanno, Makoto Tanaka, Mizuko Eiro, Masaaki Satoh, Mamoru Kazama, Junichiro James |
description | TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case. |
doi_str_mv | 10.1007/s13730-019-00400-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2231908939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</originalsourceid><addsrcrecordid>eNp9kU9LxDAQxYMo7qJ-AQ_So5fqJGnazUWQxX8gKKJ4DDGddCNtsibdFb-9XXcVvXiaGd6blyE_Qg4pnFCA6jRRXnHIgcocoADI5RYZMypZXhSF3P7Vj8hBSq8AQHkBAuQuGXEKVQWiHJPne93PQhsaZ3SbWedr55uUBZvNY2gipuSWmEX0g-r8MrRL7ND3Q5_pbK57txreXT_LHs8vH-6y9OHrGDrcJztWtwkPNnWPPF1ePE6v89u7q5vp-W1uBBN9bqkQE-CiLPiEWSYApRRUlLWlVcUMlMyUL0jR1FZoW0tuCs4YCKorCQiC75Gzde588dJhbYZzom7VPLpOxw8VtFN_Fe9mqglLVU4YlMUq4HgTEMPbAlOvOpcMtq32GBZJMcaphInkcrCytdXEkFJE-_MMBbWCotZQ1ABFfUFRq6Wj3wf-rHwjGAx8bUiD5BuM6jUs4vDf6b_YTw8umBY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2231908939</pqid></control><display><type>article</type><title>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</title><source>NCBI_PubMed Central(免费)</source><source>Springer Nature</source><creator>Saito, Hirotaka ; Tanaka, Kenichi ; Fujiwara, Momoko ; Iwasaki, Tsuyoshi ; Numata, Tokutaro ; Oda, Akira ; Kanno, Makoto ; Tanaka, Mizuko ; Eiro, Masaaki ; Satoh, Mamoru ; Kazama, Junichiro James</creator><creatorcontrib>Saito, Hirotaka ; Tanaka, Kenichi ; Fujiwara, Momoko ; Iwasaki, Tsuyoshi ; Numata, Tokutaro ; Oda, Akira ; Kanno, Makoto ; Tanaka, Mizuko ; Eiro, Masaaki ; Satoh, Mamoru ; Kazama, Junichiro James</creatorcontrib><description>TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.</description><identifier>ISSN: 2192-4449</identifier><identifier>EISSN: 2192-4449</identifier><identifier>DOI: 10.1007/s13730-019-00400-9</identifier><identifier>PMID: 31077056</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Abdominal Pain - diagnosis ; Abdominal Pain - etiology ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Case Report ; Castleman Disease - blood ; Castleman Disease - diagnosis ; Castleman Disease - drug therapy ; Castleman Disease - pathology ; Cyclosporine - administration & dosage ; Cyclosporine - therapeutic use ; Female ; Fever - diagnosis ; Fever - etiology ; Glomerulonephritis, Membranoproliferative - pathology ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - therapeutic use ; Kidney - blood supply ; Kidney - pathology ; Kidney Glomerulus - pathology ; Medicine ; Medicine & Public Health ; Methylprednisolone - administration & dosage ; Methylprednisolone - therapeutic use ; Middle Aged ; Nephrology ; Thrombocytopenia - diagnosis ; Thrombocytopenia - etiology ; Treatment Outcome ; Urology ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>CEN case reports, 2019-11, Vol.8 (4), p.239-245</ispartof><rights>Japanese Society of Nephrology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</citedby><cites>FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</cites><orcidid>0000-0003-4655-9355</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820645/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820645/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31077056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Hirotaka</creatorcontrib><creatorcontrib>Tanaka, Kenichi</creatorcontrib><creatorcontrib>Fujiwara, Momoko</creatorcontrib><creatorcontrib>Iwasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Numata, Tokutaro</creatorcontrib><creatorcontrib>Oda, Akira</creatorcontrib><creatorcontrib>Kanno, Makoto</creatorcontrib><creatorcontrib>Tanaka, Mizuko</creatorcontrib><creatorcontrib>Eiro, Masaaki</creatorcontrib><creatorcontrib>Satoh, Mamoru</creatorcontrib><creatorcontrib>Kazama, Junichiro James</creatorcontrib><title>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</title><title>CEN case reports</title><addtitle>CEN Case Rep</addtitle><addtitle>CEN Case Rep</addtitle><description>TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.</description><subject>Abdominal Pain - diagnosis</subject><subject>Abdominal Pain - etiology</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Case Report</subject><subject>Castleman Disease - blood</subject><subject>Castleman Disease - diagnosis</subject><subject>Castleman Disease - drug therapy</subject><subject>Castleman Disease - pathology</subject><subject>Cyclosporine - administration & dosage</subject><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Fever - diagnosis</subject><subject>Fever - etiology</subject><subject>Glomerulonephritis, Membranoproliferative - pathology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney - blood supply</subject><subject>Kidney - pathology</subject><subject>Kidney Glomerulus - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Thrombocytopenia - diagnosis</subject><subject>Thrombocytopenia - etiology</subject><subject>Treatment Outcome</subject><subject>Urology</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>2192-4449</issn><issn>2192-4449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kU9LxDAQxYMo7qJ-AQ_So5fqJGnazUWQxX8gKKJ4DDGddCNtsibdFb-9XXcVvXiaGd6blyE_Qg4pnFCA6jRRXnHIgcocoADI5RYZMypZXhSF3P7Vj8hBSq8AQHkBAuQuGXEKVQWiHJPne93PQhsaZ3SbWedr55uUBZvNY2gipuSWmEX0g-r8MrRL7ND3Q5_pbK57txreXT_LHs8vH-6y9OHrGDrcJztWtwkPNnWPPF1ePE6v89u7q5vp-W1uBBN9bqkQE-CiLPiEWSYApRRUlLWlVcUMlMyUL0jR1FZoW0tuCs4YCKorCQiC75Gzde588dJhbYZzom7VPLpOxw8VtFN_Fe9mqglLVU4YlMUq4HgTEMPbAlOvOpcMtq32GBZJMcaphInkcrCytdXEkFJE-_MMBbWCotZQ1ABFfUFRq6Wj3wf-rHwjGAx8bUiD5BuM6jUs4vDf6b_YTw8umBY</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Saito, Hirotaka</creator><creator>Tanaka, Kenichi</creator><creator>Fujiwara, Momoko</creator><creator>Iwasaki, Tsuyoshi</creator><creator>Numata, Tokutaro</creator><creator>Oda, Akira</creator><creator>Kanno, Makoto</creator><creator>Tanaka, Mizuko</creator><creator>Eiro, Masaaki</creator><creator>Satoh, Mamoru</creator><creator>Kazama, Junichiro James</creator><general>Springer Singapore</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4655-9355</orcidid></search><sort><creationdate>20191101</creationdate><title>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</title><author>Saito, Hirotaka ; Tanaka, Kenichi ; Fujiwara, Momoko ; Iwasaki, Tsuyoshi ; Numata, Tokutaro ; Oda, Akira ; Kanno, Makoto ; Tanaka, Mizuko ; Eiro, Masaaki ; Satoh, Mamoru ; Kazama, Junichiro James</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Abdominal Pain - diagnosis</topic><topic>Abdominal Pain - etiology</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Case Report</topic><topic>Castleman Disease - blood</topic><topic>Castleman Disease - diagnosis</topic><topic>Castleman Disease - drug therapy</topic><topic>Castleman Disease - pathology</topic><topic>Cyclosporine - administration & dosage</topic><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Fever - diagnosis</topic><topic>Fever - etiology</topic><topic>Glomerulonephritis, Membranoproliferative - pathology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney - blood supply</topic><topic>Kidney - pathology</topic><topic>Kidney Glomerulus - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Thrombocytopenia - diagnosis</topic><topic>Thrombocytopenia - etiology</topic><topic>Treatment Outcome</topic><topic>Urology</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Hirotaka</creatorcontrib><creatorcontrib>Tanaka, Kenichi</creatorcontrib><creatorcontrib>Fujiwara, Momoko</creatorcontrib><creatorcontrib>Iwasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Numata, Tokutaro</creatorcontrib><creatorcontrib>Oda, Akira</creatorcontrib><creatorcontrib>Kanno, Makoto</creatorcontrib><creatorcontrib>Tanaka, Mizuko</creatorcontrib><creatorcontrib>Eiro, Masaaki</creatorcontrib><creatorcontrib>Satoh, Mamoru</creatorcontrib><creatorcontrib>Kazama, Junichiro James</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CEN case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Hirotaka</au><au>Tanaka, Kenichi</au><au>Fujiwara, Momoko</au><au>Iwasaki, Tsuyoshi</au><au>Numata, Tokutaro</au><au>Oda, Akira</au><au>Kanno, Makoto</au><au>Tanaka, Mizuko</au><au>Eiro, Masaaki</au><au>Satoh, Mamoru</au><au>Kazama, Junichiro James</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</atitle><jtitle>CEN case reports</jtitle><stitle>CEN Case Rep</stitle><addtitle>CEN Case Rep</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>8</volume><issue>4</issue><spage>239</spage><epage>245</epage><pages>239-245</pages><issn>2192-4449</issn><eissn>2192-4449</eissn><abstract>TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31077056</pmid><doi>10.1007/s13730-019-00400-9</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4655-9355</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2192-4449 |
ispartof | CEN case reports, 2019-11, Vol.8 (4), p.239-245 |
issn | 2192-4449 2192-4449 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820645 |
source | NCBI_PubMed Central(免费); Springer Nature |
subjects | Abdominal Pain - diagnosis Abdominal Pain - etiology Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Case Report Castleman Disease - blood Castleman Disease - diagnosis Castleman Disease - drug therapy Castleman Disease - pathology Cyclosporine - administration & dosage Cyclosporine - therapeutic use Female Fever - diagnosis Fever - etiology Glomerulonephritis, Membranoproliferative - pathology Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Kidney - blood supply Kidney - pathology Kidney Glomerulus - pathology Medicine Medicine & Public Health Methylprednisolone - administration & dosage Methylprednisolone - therapeutic use Middle Aged Nephrology Thrombocytopenia - diagnosis Thrombocytopenia - etiology Treatment Outcome Urology Vascular Endothelial Growth Factor A - metabolism |
title | Pathological findings of progressive renal involvement in a patient with TAFRO syndrome |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathological%20findings%20of%20progressive%20renal%20involvement%20in%20a%20patient%20with%20TAFRO%20syndrome&rft.jtitle=CEN%20case%20reports&rft.au=Saito,%20Hirotaka&rft.date=2019-11-01&rft.volume=8&rft.issue=4&rft.spage=239&rft.epage=245&rft.pages=239-245&rft.issn=2192-4449&rft.eissn=2192-4449&rft_id=info:doi/10.1007/s13730-019-00400-9&rft_dat=%3Cproquest_pubme%3E2231908939%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2231908939&rft_id=info:pmid/31077056&rfr_iscdi=true |